PURPOSE: External-beam radiation therapy combined with low-doserate permanent brachytherapy are commonly used to treat men with localized prostate cancer. This Phase II trial was performed to document late gastrointestinal or genitourinary toxicity as well as biochemical control for this treatment in a multi-institutional cooperative group setting. This report defines the long-term results of this trial. METHODS AND MATERIALS: All eligible patients received external-beam radiation (45 Gy in 25 fractions) followed 2-6 weeks later by a permanent iodine 125 implant of 108 Gy. Late toxicity was defined by the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme. Biochemical control was defined by the American Society for Therapeutic Radiology and Oncology (ASTRO) Consensus definition and the ASTRO Phoenix definition. RESULTS: One hundred thirty-eight patients were enrolled from 20 institutions, and 131 were eligible. Median follow-up (living patients) was 8.2 years (range, 2.7-9.3 years). The 8-year estimate of late grade >3 genitourinary and/or gastrointestinal toxicity was 15%. The most common grade >3 toxicities were urinary frequency, dysuria, and proctitis. There were two grade 4 toxicities, both bladder necrosis, and no grade 5 toxicities. In addition, 42% of patients complained of grade 3 impotence (no erections) at 8 years. The 8-year estimate of biochemical failure was 18% and 21% by the Phoenix and ASTRO consensus definitions, respectively. CONCLUSION: Biochemical control for this treatment seems durable with 8 years of follow-up and is similar to high-dose external beam radiation alone or brachytherapy alone. Late toxicity in this multi-institutional trial is higher than reports from similar cohorts of patients treated with high-dose external-beam radiation alone or permanent low-doserate brachytherapy alone, perhaps suggesting further attention to strategies that limit doses to normal structures or to unimodal radiotherapy techniques. Copyright Â
PURPOSE: External-beam radiation therapy combined with low-doserate permanent brachytherapy are commonly used to treat men with localized prostate cancer. This Phase II trial was performed to document late gastrointestinal or genitourinary toxicity as well as biochemical control for this treatment in a multi-institutional cooperative group setting. This report defines the long-term results of this trial. METHODS AND MATERIALS: All eligible patients received external-beam radiation (45 Gy in 25 fractions) followed 2-6 weeks later by a permanent iodine 125 implant of 108 Gy. Late toxicity was defined by the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme. Biochemical control was defined by the American Society for Therapeutic Radiology and Oncology (ASTRO) Consensus definition and the ASTRO Phoenix definition. RESULTS: One hundred thirty-eight patients were enrolled from 20 institutions, and 131 were eligible. Median follow-up (living patients) was 8.2 years (range, 2.7-9.3 years). The 8-year estimate of late grade >3 genitourinary and/or gastrointestinal toxicity was 15%. The most common grade >3 toxicities were urinary frequency, dysuria, and proctitis. There were two grade 4 toxicities, both bladder necrosis, and no grade 5 toxicities. In addition, 42% of patients complained of grade 3 impotence (no erections) at 8 years. The 8-year estimate of biochemical failure was 18% and 21% by the Phoenix and ASTRO consensus definitions, respectively. CONCLUSION: Biochemical control for this treatment seems durable with 8 years of follow-up and is similar to high-dose external beam radiation alone or brachytherapy alone. Late toxicity in this multi-institutional trial is higher than reports from similar cohorts of patients treated with high-dose external-beam radiation alone or permanent low-doserate brachytherapy alone, perhaps suggesting further attention to strategies that limit doses to normal structures or to unimodal radiotherapy techniques. Copyright Â
Authors: John Kinahan; Howard Pai; Mildred Martens; Jason Gray; Darren Biberdorf; Alex Mihailovic; Iain McAuley Journal: Can Urol Assoc J Date: 2014 Jan-Feb Impact factor: 1.862
Authors: M E Schutzer; P F Orio; M C Biagioli; D A Asher; H Lomas; D Moghanaki Journal: Prostate Cancer Prostatic Dis Date: 2015-02-17 Impact factor: 5.554
Authors: Giovanni Fellin; Maria A Mirri; Luigi Santoro; Barbara A Jereczek-Fossa; Claudio Divan; Salvatore Mussari; Francesco Ziglio; Beniamino La Face; Fernando Barbera; Michela Buglione; Laura Bandera; Barbara Ghedi; Nadia G Di Muzio; Andrea Losa; Paola Mangili; Luciano Nava; Renato Chiarlone; Nunzia Ciscognetti; Emilio Gastaldi; Federica Cattani; Ruggero Spoto; Andrea Vavassori; Francesca R Giglioli; Alessia Guarneri; Valentina Cerboneschi; Marcello Mignogna; Mauro Paoluzzi; Valentina Ravaglia; Costanza Chiumento; Stefania Clemente; Vincenzo Fusco; Roberto Santini; Marco Stefanacci; Francesco P Mangiacotti; Marco Martini; Tiziana Palloni; Giuseppe Schinaia; Grazia Lazzari; Giovanni Silvano; Stefano Magrini; Umberto Ricardi; Riccardo Santoni; Roberto Orecchia Journal: Br J Radiol Date: 2016-07-07 Impact factor: 3.039
Authors: O Pons-Llanas; E Collado-Ballesteros; S Roldan-Ortega; A Conde-Moreno; F Celada-Alvarez; F Martínez-Arcelus; M J Pérez-Calatayud; V Carmona-Meseguer; J Gimeno-Olmos; V Forner-Ferrer; A Tormo-Micó; J Perez-Calatayud; J López-Torrecilla Journal: Rep Pract Oncol Radiother Date: 2020-05-08
Authors: I-Chow Hsu; Joseph P Rodgers; Katsuto Shinohara; James Purdy; Jeff Michalski; Mack Roach; Eric Vigneault; Robert A Ivker; Rodger M Pryzant; Michael Kuettel; Daniel Taussky; Gary S Gustafson; Adam Raben; Howard M Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2020-11-10 Impact factor: 8.013
Authors: Jennifer Ai-Lian Woo; Leonard N Chen; Hongkun Wang; Robyn A Cyr; Onita Bhattasali; Joy S Kim; Rudy Moures; Thomas M Yung; Siyuan Lei; Brian Timothy Collins; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins Journal: Front Oncol Date: 2015-03-31 Impact factor: 6.244